A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Trial Identifier: D9450C00001
Sponsor: AstraZeneca
Collaborator:
ImaginAb, Inc.
NCTID:: NCT05397171
Start Date: June 2022
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Lung Cancer; Colorectal Cancer; Bladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (Canada) Translation

Trial Locations

Country Location
CA, ON Ottawa, ON, CA, K1H 8L6
CA, Ontario Toronto, Ontario, CA, M5G 1X5
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Madrid, ES, 28040
ES Madrid, ES, 28050
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
FR Marseille, FR, 13015
FR Toulouse Cedex 9, FR, 31059
FR Villejuif Cedex, FR, 94805
GB Cambridge, GB, CB2 0QQ
GB Glasgow, GB, G12 0YN
GB LONDON, GB, NW3 2QG
GB Newcastle Upon Tyne, GB, NE7 7DN
US, CT New Haven, CT, US, 06510
US, GA Atlanta, GA, US, 30322
US, IA Iowa City, IA, US, 52242
US, MI Detroit, MI, US, 48201
US, MO Saint Louis, MO, US, 63110
US, NV Las Vegas, NV, US, 89169
US, RI Providence, RI, US, 02903
US, WA Seattle, WA, US, 98109